David Baltimore (Vincent Yu/AP Images)

Gilead’s Kite jumps back to the bar­gain­ing ta­ble to forge $875M pact with a new­ly-emerged up­start on next-gen cell ther­a­pies

Just 6 weeks af­ter strik­ing a $2.3 bil­lion deal to de­vel­op off-the-shelf cell ther­a­pies with Shore­line Bio­sciences, Gilead sub Kite Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.